Alaunos Therapeutics, Inc.
TCRT · Price history
Price at last available close
$2.06
+$1.04 (+101.96%) 1M
2026-10-27
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Alaunos Therapeutics, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 13, 2026. A research update is not a new financial filing.
Who they are
Alaunos Therapeutics, Inc. is an oncology company in the clinical trial phase, specializing in the creation of adoptive T-cell receptor (TCR) engineered therapies. Their pipeline includes a TCR Library, currently undergoing Phase I/II clinical trials, which comprises ten T-cell receptors designed to target mutated KRAS, TP53, and EGFR in various cancers such as non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. Additionally, they are advancing hunTR, a platform focused on human neoantigen T-cell receptors, and mbIL-15, intended for solid tumor treatment.
How they make money
Alaunos Therapeutics is a preclinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model focuses on the research and development of novel, orally administered small-molecule therapeutics for obesity and metabolic disorders, relying on capital raises and potential future licensing or commercialization agreements to fund operations.
Products & services
The company is developing ALN1003, an investigational oral small-molecule therapeutic candidate for the treatment of obesity and related metabolic disorders, including metabolic dysfunction-associated steatotic liver disease.
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
- Healthcare providers and patients (potential future)Source
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Contract Research Organizations (CROs) — The company utilizes various unnamed third-party contract research organizations to conduct preclinical studies and research activities.Source
Strengths
- Proprietary research focus on novel oral metabolic therapeuticsSource
Sources
Financial risk observations and what to check
These are saved observations about business performance, not predictions. Review the company filings alongside the interpretation below. Latest stored financial period end: 2026-06-30.
Opportunity Score is currently unavailable; Wall Street Score remains independently validated.
The unavailable Opportunity Score is a separate model output. It must not be substituted with zero or inferred from the company score.
Diluted weighted-average shares increased 45.1% year over year.
Compare per-share results with total earnings and inspect the equity footnote. A change in weighted-average shares does not by itself establish the cause, the number of shares issued today, or the economic effect of a split.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
23
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
30
Poor
Financial Strength
65
Business Quality / Moat
0
Management
40
Growth Quality
13
Risk / Durability
7
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Model Outlook
12-month model · What does the model think happens next?
Outperformance analysis is not currently available.
Reverse-split / listing-compliance risk: HIGH
This is a risk signal, not a prediction. It is separate from Wall Street Score and does not change the company score. It looks for listing-pressure signals such as prolonged Nasdaq trading below $1, very low share price, micro-cap size, negative free cash flow, and verified recent reverse splits.
Risk indicator: 70/100
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
A current Opportunity Score is not available.
The 12-month model outlook is not currently available.
- •Balance-sheet / debt profile scores strongly
- •M&A headline · Oct 13, 2026
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for TCRT
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •What is driving TCRT's revenue decline, and does the latest company filing suggest the weakness is temporary or structural?
- •How long can TCRT fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is TCRT likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for TCRT to reach sustainable profitability?
- •What future growth or profitability would be needed to justify TCRT's current valuation?
Essential Investment Snapshot
Wall Street Score
23
Market Cap
$6.0M
P/E Ratio
-1.6
EPS
$-1.95
52-Week High
$4.50
52-Week Low
$0.72
Beta
-0.97
Shares Outstanding
1.9M
Total Revenue
$3K
Total Debt
$0
Dividend
No current dividend
Liquidation Value / Share
$0.33
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Building upward momentum
Extreme movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for TCRT
Detected from reported data — verify before acting.M&A headline · Oct 13, 2026
Alaunos Therapeutics Announces Acquisition of Velaris Therapeutics — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
GlobeNewsWireM&A headline · Oct 13, 2026
Paragon Labs Expands Leadership Team with Former Apogee Executives; Velaris Therapeutics Acquired by Alaunos Therapeutics, Inc. — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
PRNewsWireCommunity Sentiment
0 active · 0 total callsNo personal call yet on TCRT.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary research focus on novel oral metabolic therapeutics.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −History of operating losses and expectation of continued losses.
- −Need for additional capital to fund research and development.
- −Uncertainty of clinical trial success and regulatory approval.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
3 historical score records availablePrevious Score
25
Oct 1, 2026
Change
-1.7
points
Current Score
23
Oct 22, 2026
Category Changes
TCRT decreased 1.7 points because Asset declined by 16.5 points, Capital declined by 2 points, Buffett declined by 2.5 points.
Negative Contributors
- − Asset declined by 16.5 points
- − Capital declined by 2 points
- − Buffett declined by 2.5 points
Projected Score
Projected Score
20
Projected Change
-3.6 points
Preliminary comparable-period financial changes suggest decline of approximately 3.6 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$2.06
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Large reported revenue change: -50.0%
Revenue changed sharply from 2024 to 2025. This can reflect a real business change, acquisition, divestiture, discontinued operations, restatement, or reporting-basis change. Compare the underlying filing before treating it as normal growth or decline.
TTM may combine quarters from before and after the event, so its trend can also be distorted.
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3K | $5K | $10K | $5K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $848K | $1.4M | $362K | $4.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | -$845K | -$1.4M | -$352K | -$4.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $1.6M | $1.4M | $362K | $16.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $2.4M | $2.9M | $4.5M | $12.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $3.2M | $2.9M | $4.5M | $29.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$4.0M | -$4.2M | -$4.7M | -$30.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$4.1M | -$4.2M | -$4.8M | -$34.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $0.00 | $0.00 | $0.00 | $1.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$4.0M | -$4.2M | -$4.7M | -$35.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$4.0M | -$4.2M | -$4.7M | -$35.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-1.90 | $-2.20 | $-2.92 | $-21.97 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 2.43M | 1.95M | 1.60M | 1.60M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 2.43M | 1.95M | 1.60M | 1.60M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$0
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.41
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
Not available
Cash Change
-95.7%
Margin Change
Not available
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Weakened
- Cash position declined
Potential Score Impact
Pressure indicators included EPS growth, cash levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
EPS declined 34.9%. Cash declined 95.7%.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
3 historical recordsHistorical Score Chart
3 of 3 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Why is Alaunos Therapeutics Stock Trading 200% Higher on Tuesday?
Alaunos Therapeutics Announces Acquisition of Velaris Therapeutics
Paragon Labs Expands Leadership Team with Former Apogee Executives; Velaris Therapeutics Acquired by Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rules
Rumor Mill · TCRT
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial